DK3386591T3 - Heteroaromatic nmda receptor modulators and uses thereof - Google Patents
Heteroaromatic nmda receptor modulators and uses thereof Download PDFInfo
- Publication number
- DK3386591T3 DK3386591T3 DK16820103.6T DK16820103T DK3386591T3 DK 3386591 T3 DK3386591 T3 DK 3386591T3 DK 16820103 T DK16820103 T DK 16820103T DK 3386591 T3 DK3386591 T3 DK 3386591T3
- Authority
- DK
- Denmark
- Prior art keywords
- heteroaromatic
- nmda receptor
- receptor modulators
- nmda
- modulators
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562265182P | 2015-12-09 | 2015-12-09 | |
PCT/US2016/065852 WO2017100591A1 (en) | 2015-12-09 | 2016-12-09 | Heteroaromatic nmda receptor modulators and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3386591T3 true DK3386591T3 (da) | 2020-09-28 |
Family
ID=57681781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16820103.6T DK3386591T3 (da) | 2015-12-09 | 2016-12-09 | Heteroaromatic nmda receptor modulators and uses thereof |
Country Status (13)
Country | Link |
---|---|
US (3) | US10626122B2 (da) |
EP (1) | EP3386591B1 (da) |
JP (1) | JP7071917B2 (da) |
CY (1) | CY1123359T1 (da) |
DK (1) | DK3386591T3 (da) |
ES (1) | ES2821010T3 (da) |
HR (1) | HRP20201522T1 (da) |
HU (1) | HUE051395T2 (da) |
LT (1) | LT3386591T (da) |
PT (1) | PT3386591T (da) |
RS (1) | RS60834B1 (da) |
SI (1) | SI3386591T1 (da) |
WO (1) | WO2017100591A1 (da) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3386591T3 (da) | 2015-12-09 | 2020-09-28 | Cadent Therapeutics Inc | Heteroaromatic nmda receptor modulators and uses thereof |
EP3386990B1 (en) | 2015-12-09 | 2023-04-19 | Novartis AG | Thienopyrimidinone nmda receptor modulators and uses thereof |
WO2018119374A1 (en) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics | Nmda receptor modulators and uses thereof |
PE20210948A1 (es) * | 2018-08-03 | 2021-05-24 | Cadent Therapeutics Inc | Moduladores del receptor nmda heteroaromatico y usos de los mismos |
US11358971B2 (en) * | 2019-07-03 | 2022-06-14 | H. Lundbeck A/S | Prodrugs of modulators of the NMDA receptor |
CA3182133A1 (en) * | 2020-06-29 | 2022-01-06 | Council Of Scientific & Industrial Research | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4921854A (en) | 1986-12-30 | 1990-05-01 | Egis Gyogyszergyar | Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds |
WO1998000401A1 (en) | 1996-06-28 | 1998-01-08 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
JP2004501901A (ja) | 2000-06-26 | 2004-01-22 | メルク エンド カムパニー インコーポレーテッド | イミノピリミジン系nmdanr2b受容体拮抗薬 |
WO2003024955A2 (en) | 2001-09-18 | 2003-03-27 | Sunesis Pharmaceuticals, Inc. | Small molecule inhibitors of caspases |
AR038118A1 (es) | 2002-01-14 | 2004-12-29 | Upjohn Co | Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales |
EP1768960A1 (en) | 2004-07-13 | 2007-04-04 | F.Hoffmann-La Roche Ag | Sulfonamide derivatives |
TW200643015A (en) * | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
AR056155A1 (es) | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica |
WO2008033757A2 (en) | 2006-09-11 | 2008-03-20 | N.V. Organon | 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives |
KR20090107994A (ko) * | 2006-09-11 | 2009-10-14 | 엔.브이.오가논 | 퀴나졸리논 및 이소퀴놀리논 아세트아미드 유도체 |
CA2672893C (en) | 2006-12-15 | 2016-02-23 | Abraxis Bioscience, Inc. | Triazine derivatives and their therapeutical applications |
AU2008214372A1 (en) | 2007-02-08 | 2008-08-14 | Merck Sharp & Dohme Corp. | Therapeutic agents |
US9034907B2 (en) | 2007-04-18 | 2015-05-19 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
WO2008138126A1 (en) | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
EP2190428A4 (en) | 2007-08-21 | 2012-02-29 | Merck Sharp & Dohme | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYLPEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES |
TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
KR20110007235A (ko) | 2008-05-01 | 2011-01-21 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 퀴놀린 및 관련 유사체 |
CN102112475A (zh) | 2008-05-29 | 2011-06-29 | 西特里斯药业公司 | 作为沉默调节蛋白调节剂的咪唑并吡啶和相关的类似物 |
JP5758292B2 (ja) | 2008-07-03 | 2015-08-05 | サートリス ファーマシューティカルズ, インコーポレイテッド | サーチュイン調節薬としてのベンズイミダゾールおよび関連する類似体 |
SG196776A1 (en) | 2008-09-29 | 2014-02-13 | Sirtris Pharmaceuticals Inc | Quinazolinone, quinolone and related analogs as sirtuin modulators |
EA020460B1 (ru) | 2009-01-12 | 2014-11-28 | Пфайзер Лимитед | Производные сульфонамида |
WO2010111573A1 (en) | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
EP2264035A1 (en) | 2009-06-04 | 2010-12-22 | Merz Pharma GmbH & Co. KGaA | Glycine B antagonists |
TW201116532A (en) | 2009-08-05 | 2011-05-16 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
MX2012004289A (es) | 2009-10-13 | 2012-06-12 | Msd Oss Bv | Derivados de azina condensada para el tratamiento de enfermedades relacionadas con el receptor de acetilcolina. |
WO2011117382A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | Pyridyltriazoles |
WO2011117381A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | B-raf kinase inhibitors |
JP2013540145A (ja) | 2010-10-21 | 2013-10-31 | ウニベルシテート デス ザールランデス | コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤 |
US20120165330A1 (en) | 2010-12-22 | 2012-06-28 | Sirtris Pharmaceuticals, Inc. | Quinazolinone and related analogs as sirtuin modulators |
US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
NZ617987A (en) * | 2011-05-10 | 2016-02-26 | Gilead Sciences Inc | Fused heterocyclic compounds as sodium channel modulators |
US9493412B2 (en) | 2011-09-27 | 2016-11-15 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
EP2760840B1 (en) | 2011-09-30 | 2015-08-12 | Bristol-Myers Squibb Company | Quinolinone carboxamide inhibitors of endothelial lipase |
EP2760839B1 (en) | 2011-09-30 | 2015-11-25 | Bristol-Myers Squibb Company | Pyridinedione carboxamide inhibitors of endothelial lipase |
CN102336768A (zh) | 2011-10-24 | 2012-02-01 | 中国科学院上海有机化学研究所 | N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途 |
JP6114297B2 (ja) | 2011-11-11 | 2017-04-12 | ギリアド アポロ, エルエルシー | Acc阻害剤およびその使用 |
WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
WO2014179144A1 (en) | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
MX362582B (es) | 2013-06-28 | 2019-01-24 | Beigene Ltd | Compuestos triciclicos fusionados de urea como inhibidores de raf quinasa y/o dimero de raf quinasa. |
WO2015007453A1 (en) * | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
WO2015048503A2 (en) | 2013-09-26 | 2015-04-02 | Mnemosyne Pharmaceuticals, Inc. | N-arylmethyl sulfonamide negative modulators of nr2a |
DK3055315T3 (da) | 2013-10-11 | 2018-10-22 | Hoffmann La Roche | Thiazolopyrimidinoner som modulatorer af NMDA-receptoraktivitet |
CN103664877A (zh) | 2013-12-25 | 2014-03-26 | 重庆医药工业研究院有限责任公司 | 一种喹啉衍生物、其制备方法和应用 |
WO2016034703A1 (en) * | 2014-09-05 | 2016-03-10 | AbbVie Deutschland GmbH & Co. KG | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases |
WO2016081649A1 (en) | 2014-11-18 | 2016-05-26 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto |
MX2018004553A (es) | 2015-10-16 | 2019-04-15 | Univ Northwestern | Combinación farmacéutica de un antipsicótico atípico y un modulador de nmda para el tratamiento de esquizofrenia, trastorno bipolar, deterioro cognitivo y trastorno depresivo mayor. |
EP3386990B1 (en) | 2015-12-09 | 2023-04-19 | Novartis AG | Thienopyrimidinone nmda receptor modulators and uses thereof |
DK3386591T3 (da) * | 2015-12-09 | 2020-09-28 | Cadent Therapeutics Inc | Heteroaromatic nmda receptor modulators and uses thereof |
US20170305861A1 (en) | 2016-04-25 | 2017-10-26 | Immunomet Therapeutics, Inc | Heteroaryl compounds comprising nitrogen and use thereof |
WO2018026371A1 (en) | 2016-08-04 | 2018-02-08 | Sunovion Pharmaceuticals Inc. | Dual nav1.2/5ht2a inhibitors for treating cns disorders |
WO2018119374A1 (en) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics | Nmda receptor modulators and uses thereof |
PE20210948A1 (es) * | 2018-08-03 | 2021-05-24 | Cadent Therapeutics Inc | Moduladores del receptor nmda heteroaromatico y usos de los mismos |
-
2016
- 2016-12-09 DK DK16820103.6T patent/DK3386591T3/da active
- 2016-12-09 JP JP2018529995A patent/JP7071917B2/ja active Active
- 2016-12-09 HU HUE16820103A patent/HUE051395T2/hu unknown
- 2016-12-09 SI SI201630931T patent/SI3386591T1/sl unknown
- 2016-12-09 EP EP16820103.6A patent/EP3386591B1/en active Active
- 2016-12-09 PT PT168201036T patent/PT3386591T/pt unknown
- 2016-12-09 WO PCT/US2016/065852 patent/WO2017100591A1/en active Application Filing
- 2016-12-09 RS RS20201142A patent/RS60834B1/sr unknown
- 2016-12-09 ES ES16820103T patent/ES2821010T3/es active Active
- 2016-12-09 US US16/060,056 patent/US10626122B2/en active Active
- 2016-12-09 LT LTEP16820103.6T patent/LT3386591T/lt unknown
-
2020
- 2020-01-31 US US16/779,517 patent/US11236104B2/en active Active
- 2020-09-23 HR HRP20201522TT patent/HRP20201522T1/hr unknown
- 2020-09-23 CY CY20201100895T patent/CY1123359T1/el unknown
-
2021
- 2021-12-14 US US17/550,435 patent/US20230023543A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2018536685A (ja) | 2018-12-13 |
SI3386591T1 (sl) | 2020-11-30 |
ES2821010T3 (es) | 2021-04-23 |
RS60834B1 (sr) | 2020-10-30 |
US10626122B2 (en) | 2020-04-21 |
EP3386591B1 (en) | 2020-06-24 |
WO2017100591A1 (en) | 2017-06-15 |
CY1123359T1 (el) | 2021-12-31 |
PT3386591T (pt) | 2020-10-01 |
US20210107916A1 (en) | 2021-04-15 |
US20180362541A1 (en) | 2018-12-20 |
HRP20201522T1 (hr) | 2020-12-11 |
HUE051395T2 (hu) | 2021-03-01 |
JP7071917B2 (ja) | 2022-05-19 |
US20230023543A1 (en) | 2023-01-26 |
LT3386591T (lt) | 2020-10-12 |
US11236104B2 (en) | 2022-02-01 |
EP3386591A1 (en) | 2018-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201807731B (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MA43382A (fr) | Modulateurs des récepteurs des chimiokines | |
IL264514A (en) | Spiro-lactam modulates and uses of the nmda receptor | |
MA53943A (fr) | Modulateurs de ror-gamma | |
DK3149042T3 (da) | PD-L1-antistoffer og anvendelser deraf | |
IL240166A0 (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
IL264488A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MA55328A (fr) | Modulateurs de ror-gamma | |
IL286107A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
IL240164A0 (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
CL2018000700A1 (es) | Sililfenoxiheterociclos trisustituidos y análogos | |
IL240163B (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
HK1255160A1 (zh) | 取代的4-氮雜吲哚以及它們作為glun2b受體調節劑的用途 | |
IL240162B (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
IL240165A0 (en) | spiro-lactam modulators of the NMDA receptor and their uses | |
DK3490986T3 (da) | Piperidin-cxcr7-receptormodulatorer | |
EP3490994C0 (en) | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND THEIR USE | |
DK3386591T3 (da) | Heteroaromatic nmda receptor modulators and uses thereof | |
HK1245259A1 (zh) | 作為nmda受體調節劑的吡啶並嘧啶酮類及它們的用途 | |
PL3347376T3 (pl) | Nowy receptor IGFR-podobny i jego zastosowania | |
TH1601002410A (th) | สารปรับเปลี่ยนตัวรับ nmda และโพรดรัก, เกลือ, และการใช้สิ่งเหล่านี้ |